Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Potent antiviral HIV-1 protease inhibitor combats highly drug resistant mutant PR20

Journal Article · · Biochemical and Biophysical Research Communications
Drug-resistance threatens effective treatment of HIV/AIDS. Clinical inhibitors, including darunavir (1), are ineffective for highly resistant protease mutant PR20, however, here antiviral compound 2 derived from 1 with fused tricyclic group at P2, extended amino-benzothiazole P2’ ligand and two fluorine atoms on P1 shows 16-fold better inhibition of PR20 enzyme activity. Crystal structures of PR20 and wild-type PR complexes reveal how the extra groups of 2 counteract the expanded ligand-binding pocket, dynamic flaps, and faster dimer dissociation of PR20.
Research Organization:
Argonne National Laboratory (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
Sponsoring Organization:
National Institutes of Health (NIH); USDOE Office of Science (SC), Basic Energy Sciences (BES)
Grant/Contract Number:
W-31109-ENG-38
OSTI ID:
1572565
Alternate ID(s):
OSTI ID: 1703108
Journal Information:
Biochemical and Biophysical Research Communications, Journal Name: Biochemical and Biophysical Research Communications Journal Issue: 1 Vol. 519; ISSN 0006-291X
Publisher:
ElsevierCopyright Statement
Country of Publication:
United States
Language:
ENGLISH